SENTARA COMMUNITY PLAN (MEDICAID)

PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

<u>Directions</u>: <u>The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request</u>. All other information may be filled in by office staff; <u>fax to 1-800-750-9692</u>. No additional phone calls will be necessary if all information (<u>including phone and fax #s</u>) on this form is correct. <u>If the information provided is not complete, correct, or legible, the authorization process can be delayed.</u>

Drug Requested: Symdeko® (tezacaftor/ivacaftor)

MEMBER & PRESCRIBER INFORM	MATION: Authorization may be delayed if incomplete.
Member Name:	
Member Sentara #:	Date of Birth:
Prescriber Name:	
Prescriber Signature:	Date:
Office Contact Name:	
Phone Number:	Fax Number:
DEA OR NPI #:	
DRUG INFORMATION: Authorization	may be delayed if incomplete.
Drug Form/Strength:	
Dosing Schedule:	Length of Therapy:
Diagnosis:	ICD Code, if applicable:
Weight:	Date:
Recommended dose: 1 tablet (tezacaftor 10 150mg in the evening (approximately 12 hours	Omg/ivacaftor 150mg) in the morning and 1 tablet (ivacaftor sapart).
	ll that apply. All criteria must be met for approval. To ncluding lab results, diagnostics, and/or chart notes, must be
<u>Authorization Approval Length</u> : ON	E (1) Year
1. Does member have a diagnosis of Cystic	Fibrosis?
AND	

(Continued on next page)

2.	Is member 6 years or older?		Yes		No	
	AND					
3. Is member homozygous for the F508del mutation in the CFTR gene as confirmed by an FDA-cleared CF mutation test? (Document required ; include a copy of the test with this request) 2. Yes 2. No						
	OR					
4. Does member have <u>one (1)</u> of the following mutations in the CFTR gene as confirmed by an FDA-cleared CF mutation test: E56K, P67L, R74W, D110E, D110H, R117C, E193K, L206W, R347H, R352Q, A455E, D579G, 711+3A→G, 3272-26A→G, or 3849+10kbc→T? (Document required; include a copy of the test with this request) □ Yes □ No						
	AND					
5.	Has baseline ALT and AST testing been done? (Documentation required; incluwith this request)		Yes		ne test No	
For Reauthorization approval - liver function testing (LFT) documentation is required						
Medication being provided by a Specialty Pharmacy - PropriumRx						
	Use of samples to initiate therapy does not meet step edit/preauthori vious therapies will be verified through pharmacy paid claims or sub					